NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$53.77

+1.14 (+2.17%)

(As of 09/22/2023 ET)

Compare

Today's Range: $52.75
▼
$54.73
50-Day Range: $52.63
▼
$63.52
52-Week Range: $42.01
▼
$67.05

Volume: 612,087 shs
Average Volume: 605,342 shs
Market Capitalization: $5.16 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $78.78

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 46.5% Upside
$78.78 Price Target
Short Interest: Bearish
2.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 0.56
Based on 7 Articles This Week
Insider Trading: Selling Shares
$6.36 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.08) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

230th out of 965 stocks

Pharmaceutical Preparations Industry

91st out of 456 stocks

3.5

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $78.78, Intra-Cellular Therapies has a forecasted upside of 46.5% from its current price of $53.77.
Amount of Analyst Coverage
Intra-Cellular Therapies has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.66% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently increased by 0.39%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

3.1

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.
Search Interest
3 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
3 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,359,174.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
86.94% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.08) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Price History

30 days | 90 days | 365 days | Advanced Chart

ITCI Stock News Headlines

September 21, 2023 | americanbankingnews.com

Sharon Mates Sells 55,587 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

September 20, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 24, 2023 | Stansberry Research (Ad)

Experts: NVIDIA Now "Too Big to Succeed"

Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.

September 20, 2023 | gurufocus.com

Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc

September 11, 2023 | benzinga.com

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

September 5, 2023 | finance.yahoo.com

Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term

September 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendation

September 24, 2023 | Legacy Research (Ad)

ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing

In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.

August 12, 2023 | seekingalpha.com

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

August 4, 2023 | finance.yahoo.com

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

August 3, 2023 | seekingalpha.com

Intra-Cellular Therapies Q2 2023 Earnings Preview

July 28, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

July 6, 2023 | markets.businessinsider.com

Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know

June 22, 2023 | markets.businessinsider.com

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

June 20, 2023 | finance.yahoo.com

Drug Stock Poised For Growth With Record Sales, Strong Outlook

June 5, 2023 | finance.yahoo.com

ITCI Jul 2023 65.000 call

June 5, 2023 | msn.com

JP Morgan Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

June 5, 2023 | markets.businessinsider.com

Analyst Expectations for Intra-Cellular Therapies's Future

June 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 8, 2023 | msn.com

Mizuho Maintains Intra-Cellular Therapies (ITCI) Buy Recommendation

May 8, 2023 | finance.yahoo.com

Investing in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gain

May 5, 2023 | msn.com

Cantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

May 5, 2023 | msn.com

RBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform Recommendation

May 4, 2023 | finance.yahoo.com

‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protection

See More Headlines

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings: 8/03/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 561
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $78.78
High Stock Price Forecast: $98.00
Low Stock Price Forecast: $62.00
Forecasted Upside/Downside: +46.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-256,260,000.00
Net Margins: -50.40%
Pretax Margin: -50.36%
Return on Equity: -28.63%
Return on Assets: -24.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.58
Quick Ratio: 7.13

Sales & Book Value

Annual Sales: $250.31 million
Price / Sales: 20.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.93 per share
Price / Book: 7.76

Miscellaneous

Outstanding Shares: 95,930,000
Free Float: 92,665,000
Market Cap: $5.16 billion
Optionable: Optionable
Beta: 1.10

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Sharon Mates Ph.D. (Age 70)
Co-Founder, Chairman, CEO & Pres
Comp: $2.23M

Mr. Lawrence J. Hineline CPA (Age 67)
CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
Comp: $820.53k

Mr. Michael I. Halstead J.D. (Age 50)
Exec. VP, Gen. Counsel & Sec.
Comp: $983.65k

Dr. Suresh K. Durgam M.D. (Age 54)
Exec. VP & Chief Medical Officer
Comp: $961.84k

Mr. Mark Neumann (Age 60)
EVP & Chief Commercial Officer
Comp: $998.36k

Dr. Robert E. Davis Ph.D. (Age 72)
Sr. VP & Chief Scientific Officer

Mr. Juan Fernando Sanchez (Age 52)
VP of Corp. Communications & Investor Relations

Ms. Karen Patruno Sheehy Esq. (Age 61)
Sr. VP & Chief Compliance Officer

Dr. Michael Olchaskey
Sr. VP & Head of Regulatory Affairs

Mr. John A. Bardi
Sr. VP of Market Access, Policy & Gov. Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price forecast for 2023?: 8 equities research analysts have issued 12 month target prices for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they expect the company's stock price to reach $78.78 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2023?: Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 1.6% and is now trading at $53.77.
View the best growth stocks for 2023 here.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company had revenue of $110.80 million for the quarter, compared to analysts' expectations of $106.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 28.63% and a negative net margin of 50.40%. The business's revenue for the quarter was up 99.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.92) EPS.
What ETFs hold Intra-Cellular Therapies' stock?: ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
What is Intra-Cellular Therapies' stock symbol?: Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
Who are Intra-Cellular Therapies' major shareholders?: Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.91%), Wasatch Advisors LP (3.63%), Bellevue Group AG (3.34%), State Street Corp (2.20%), Alliancebernstein L.P. (2.13%) and JPMorgan Chase & Co. (2.06%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intra-Cellular Therapies' stock price today?: One share of ITCI stock can currently be purchased for approximately $53.77.
How much money does Intra-Cellular Therapies make?: Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.
How many employees does Intra-Cellular Therapies have?: The company employs 561 workers across the globe.
How can I contact Intra-Cellular Therapies?: Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial